Solid Biosciences (SLDB) Income from Continuing Operations (2017 - 2026)

Solid Biosciences has disclosed Income from Continuing Operations across 10 years of filings, most recently posting 55244000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 55244000.0, down 46.07% year-over-year; the trailing twelve-month figure through Mar 2026 was 186523000.0 (down 39.08% YoY), and the FY2025 annual result was 169099000.0, down 40.22% from the prior year.
• Income from Continuing Operations came in at 55244000.0 for Q1 2026 at Solid Biosciences, down from 47356000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 20397000.0 in Q3 2022 to a low of 55244000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 30352000.0 (2023), against an average of 32111058.82.
• Across the five-year window, Income from Continuing Operations soared 37.62% in 2023 and slumped 84.64% in 2024, its largest moves.
• Solid Biosciences' Income from Continuing Operations stood at 33032000.0 in 2022, then jumped by 37.62% to 20606000.0 in 2023, then plunged by 84.64% to 38046000.0 in 2024, then declined by 24.47% to 47356000.0 in 2025, then dropped by 16.66% to 55244000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 55244000.0 (Q1 2026), 47356000.0 (Q4 2025), and 45136000.0 (Q3 2025), per Business Quant data.